← Browse by Condition
Medical Condition

platelet aggregation inhibitors

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for platelet aggregation inhibitors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — platelet aggregation inhibitors Clinical Trials

How many clinical trials are currently recruiting for platelet aggregation inhibitors?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for platelet aggregation inhibitors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for platelet aggregation inhibitors?
platelet aggregation inhibitors research spans Phase 1 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a platelet aggregation inhibitors clinical trial?
Eligibility criteria for platelet aggregation inhibitors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Top Sponsors
Massachusetts General Hospital 1 trial
Montreal Heart Institute 1 trial

Recruiting Clinical Trials

NCT07613840
Recruiting
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
Enrollment
484 pts
Location
United States
Sponsor
Massachusetts General Hospital
View Trial →
NCT05702463 Phase 1
Recruiting
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II
Enrollment
30 pts
Location
Canada
Sponsor
Montreal Heart Institute
View Trial →

Related Conditions

peripheral arterial disease pad (1) amputation (1) thrombosis (1) thrombosis stent thrombosis (1) thromboelastography teg (1) pru platelet reactivity unit (1) platelet aggregation (1) type 2 diabetes (1) aspirin (1) diabetes mellitus type 2 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology